Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors.

ABSTRACT: Immunotherapies based on immune checkpoint blockade have shown remarkable clinical outcomes and durable responses in patients with many tumor types. Nevertheless, these therapies lack efficacy in most cancer patients, even causing severe adverse events in a small subset of patients, such as inflammatory disorders and hyper-progressive disease. To diminish the risk of developing serious toxicities, intratumor delivery of monoclonal antibodies could be a solution. Encouraging results have been shown in both preclinical and clinical studies. Thus, intratumor immunotherapy as a new strategy may retain efficacy while increasing safety. This approach is still an exploratory frontier in cancer research and opens up new possibilities for next-generation personalized medicine. Local intratumor deli

SUBMITTER: Blanco E 

PROVIDER: S-EPMC9917067 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature